Karadag Fisun, Ozcan Hatice, Karul Aslihan B, Yilmaz Mustafa, Cildag Orhan
Department of Chest Diseases, Faculty of Medicine, School of Medicine, Adnan Menderes University, Aydin 09010, Turkey.
Respir Med. 2007 Jul;101(7):1439-46. doi: 10.1016/j.rmed.2007.01.016. Epub 2007 Mar 7.
Non-thyroidal illness syndrome (NTIS) is frequently detected in chronic, systemic diseases. The objectives of the current study is to assess the alterations of thyroid hormones during exacerbation period, recovery of exacerbation and stable phase of chronic obstructive pulmonary disease (COPD) and correlates of these hormonal alterations. A total of 83 stable COPD patients, 20 patients with acute exacerbation and 30 control subjects were evaluated. TT3, fT3, TT3/TT4 levels of both stable and exacerbation COPD groups were lower than control subjects. TSH was also decreased during exacerbation period. In follow-up of COPD exacerbation group, TSH, TT3, fT3 and TT3/TT4 were found to be increased in measurements on the day of discharge from hospital and after 1 month, compared to baseline values. TT3 and TT3/TT4 were lower in severe COPD; whereas TSH, fT3, TT3 and TT3/TT4 were lower in patients with severe hypoxemia. IL-6 and TNF-alpha were higher in both stable and exacerbation phase COPD groups and IL-6 was correlated to TT3 in stable COPD. As a result, there are significant alterations in thyroid hormones of stable COPD patients, which are related to severity of disease and hypoxemia. The hormonal changes are more significant during exacerbation and partially regress after 1 month when the disease is stabilized. We conclude that COPD patients should not be evaluated for thyroid disease during exacerbation of the disease, and thyroid function alterations during stable phase of the disease should be considered cautiously, since thyroid function abnormalities in non-thyroid illness may mimic or mask biochemical abnormalities observed in true thyroid disease.
非甲状腺疾病综合征(NTIS)在慢性全身性疾病中经常被检测到。本研究的目的是评估慢性阻塞性肺疾病(COPD)急性加重期、加重期恢复及稳定期甲状腺激素的变化以及这些激素变化的相关性。共评估了83例稳定期COPD患者、20例急性加重期患者和30例对照者。稳定期和急性加重期COPD组的总三碘甲状腺原氨酸(TT3)、游离三碘甲状腺原氨酸(fT3)、TT3/总甲状腺素(TT4)水平均低于对照者。急性加重期促甲状腺激素(TSH)也降低。在COPD急性加重期组的随访中,发现出院当天及1个月后的测量中,TSH、TT3、fT3和TT3/TT4较基线值升高。重度COPD患者的TT3和TT3/TT4较低;而重度低氧血症患者的TSH、fT3、TT3和TT3/TT4较低。稳定期和急性加重期COPD组的白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)均较高,且稳定期COPD患者中IL-6与TT3相关。结果显示,稳定期COPD患者的甲状腺激素有显著变化,这与疾病严重程度和低氧血症有关。激素变化在急性加重期更为显著,疾病稳定1个月后部分消退。我们得出结论,COPD患者在疾病急性加重期不应进行甲状腺疾病评估,且疾病稳定期的甲状腺功能改变应谨慎考虑,因为非甲状腺疾病中的甲状腺功能异常可能会模拟或掩盖真正甲状腺疾病中观察到的生化异常。